Clinical Trial for Evaluating the Effectiveness and Safety of Online caIMR in STEMI Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

335 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-11-01

Study Completion Date

2025-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Despite the success of restoration of epicardial blood flow by the primary percutaneous coronary intervention (PPCI), approximately a half of patients with ST-segment elevation myocardial infarction (STEMI) have failed myocardial reperfusion, as reflected by microvascular obstruction (MVO) and intramyocardial haemorrhage (IMH). The coronary angiography-derived index of microvascular resistance (caIMR) is a brand new method for assessing coronary microcirculation in ischemia and no obstructive coronary artery disease (INOCA). In this trial, the investigators aim to verify the safety and effectiveness of caIMR in STEMI who underwent primary PCI. The investigators will immediately measure the caIMR of patients who successfully underwent pPCI, and combine the caIMR with the long-term prognosis, to verify the prognostic performance of caIMR.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study on the Improvement of Myocardial Microcirculation After Acute Anterior Myocardial Infarction

NCT06154395

Intravascular Imaging and Microvascular Obstruction

RECRUITING NA

A Multi-center, Real-World Clinical Trial of caIMR on Two Specific Kinds of Patients.

NCT06945094

Coronary Microvascular Dysfunction (CMD) Stable Angina Pectoris Unstable Angina Pectoris +1 more

NOT_YET_RECRUITING

Quantitative Fractional Ratio-guided Revascularization in STEMI Patients With Multi-vessel Disease

NCT04259853

ST Elevation Myocardial Infarction Multi-Vessel Coronary Artery Stenosis

ENROLLING_BY_INVITATION NA

Coronary Microcirculation Assessment After Primary Angioplasty in Myocardial Infarction

NCT04542889

STEMI - ST Elevation Myocardial Infarction

TERMINATED NA

Index of Microcirculatory Resistance After Immediate Versus Deferred Stenting in Patients With Acute Myocardial Infarction

NCT03238508

Acute Myocardial Infarction

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Despite the success of restoration of epicardial blood flow by the primary percutaneous coronary intervention (PPCI), approximately a half of patients with ST-segment elevation myocardial infarction (STEMI) have failed myocardial reperfusion, as reflected by microvascular obstruction (MVO) and intramyocardial haemorrhage (IMH). There are many defects in the current measurement technology, such as non-timely, long measurement time, high price, potential risk of gadolinium contrast agent.

The index of microcirculatory resistance (IMR) is a readily available, wire-based approach for assessing microvascular dysfunction immediately post-stenting for STEMI. The parameter has been used to characterize MVO, was associated with infarct size, and subsequent cardiac death and heart failure. However, the application of IMR in clinical practice remains limited, primarily due to the requirement of a pressure-temperature sensor wire and hyperaemic agents, which add complexity and time.

The development of functional coronary angiography has enabled the estimation of IMR based on angiography alone. The coronary angiography-derived index of microvascular resistance (caIMR) has shown good diagnostic accuracy compared with wire-based invasive IMR. This simple alternative index showed an association with extent of MVO and was of prognostic importance. In this trial, the investigators aim to verify the safety and effectiveness of caIMR in STEMI who underwent primary PCI. The investigators will immediately measure the caIMR of patients who successfully underwent pPCI, and combine the caIMR with the long-term prognosis, to verify the prognostic performance of caIMR.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Microvascular Coronary Artery Disease STEMI

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

high caIMR

caIMR≥25

Non-intervention

Intervention Type OTHER

non-intervention

low caIMR

caIMR\<25

Non-intervention

Intervention Type OTHER

non-intervention

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Non-intervention

non-intervention

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged between 18 and 80, regardless of gender;
* Initially diagnosed as STEMI and underwent primary PCI;
* Voluntarily participated in this trial and signed the informed consent form.

Exclusion Criteria

* Coronary angiography shows that PCI is not suitable;
* Past history of coronary artery bypass grafting (CABG);
* Past history of heart failure;
* Past history of myocardial infarction;
* Primary or secondary cardiomyopathy or heart valve disease;
* Patients with renal insufficiency (eGFR\<30ml/min (1.73m\^2)) or patients undergoing dialysis;
* Cardiogenic shock
* Persistent left or right coronary ostium lesion after target vessel PCI;
* Immediate effect of target vessel PCI is unsatisfactory \[such as thrombolysis in myocardial infarction (TIMI) flow \< grade 2, dissection that restricted blood flow, side branch occlusion (diameter\>1.5mm), exist distal embolism or angiographically visible thrombus\];
* Target vessel exist coronary fistula or myocardial bridge (lumen constriction \>50%);
* The target vessel cannot clearly expose the lesion in two positions with an included angle ≥ 30 degrees;
* Severe systemic infection
* Patients with malignant wasting disease, with an estimated survival of less than 1 year;
* The subject is participating in another clinical researches, and the primary endpoint has not been reached;
* The investigator believes that the subject has other conditions that are not suitable for clinical trials.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.